These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
102 related articles for article (PubMed ID: 6090048)
1. Effect of cytotoxic chemotherapy on hepatitis B viral markers in patients with hepatocellular carcinoma. Zaman S; Melia W; Johnson P; White Y; Williams R Clin Oncol; 1984 Sep; 10(3):247-52. PubMed ID: 6090048 [TBL] [Abstract][Full Text] [Related]
2. Hepatitis B viral markers in patients with primary hepatocellular carcinoma in Taiwan. Chien MC; Tong MJ; Lo KJ; Lee JK; Milich DR; Vyas GN; Murphy BL J Natl Cancer Inst; 1981 Mar; 66(3):475-9. PubMed ID: 6162990 [TBL] [Abstract][Full Text] [Related]
3. Hepatitis Be antigen and antibody in chronic liver diseases and hepatocellular carcinoma. Chen DS; Sung JL; Lai MY Hepatogastroenterology; 1981 Dec; 28(6):288-91. PubMed ID: 6284625 [TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus e antigen and primary hepatocellular carcinoma. Lin TM; Chen CJ; Lu SN; Chang AS; Chang YC; Hsu ST; Liu JY; Liaw YF; Chang WY Anticancer Res; 1991; 11(6):2063-5. PubMed ID: 1663719 [TBL] [Abstract][Full Text] [Related]
5. Tissue markers of hepatitis B virus infection in hepatocellular carcinoma and cirrhosis. Craxi A; Pasqua P; Giannuoli G; Di Stefano R; Simonetti RG; Pagliaro L Hepatogastroenterology; 1984 Apr; 31(2):55-9. PubMed ID: 6327478 [TBL] [Abstract][Full Text] [Related]
6. HBeAg/anti-HBe system and development of primary hepatocellular carcinoma in patients with HBsAg-positive liver cirrhosis. Musca A; Cordova C; Barnaba V; Bonavita MS; Levrero M; Zaccari C; Balsano F Hepatogastroenterology; 1983 Feb; 30(1):3-5. PubMed ID: 6299916 [TBL] [Abstract][Full Text] [Related]
7. HBsAg-negative hepatitis B virus infections in hepatitis C virus-associated hepatocellular carcinoma. Momosaki S; Nakashima Y; Kojiro M; Tabor E J Viral Hepat; 2005 May; 12(3):325-9. PubMed ID: 15850475 [TBL] [Abstract][Full Text] [Related]
9. Seroprevalence of hepatitis B and C viral markers in patients with primary hepatocellular carcinoma in Singapore. Khin LW; Teo CJ; Guan R Singapore Med J; 1996 Oct; 37(5):492-6. PubMed ID: 9046201 [TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus reactivation in patients receiving chemotherapy for malignancies: role of precore stop-codon and basic core promoter mutations. Alexopoulou A; Theodorou M; Dourakis SP; Karayiannis P; Sagkana E; Papanikolopoulos K; Archimandritis AJ J Viral Hepat; 2006 Sep; 13(9):591-6. PubMed ID: 16907845 [TBL] [Abstract][Full Text] [Related]
11. HBV-DNA in sera of patients with HBsAg-positive primary liver cell carcinoma. Theilmann L; Gmelin K; Will H; Czygan P; Hasche G; Doerr HW; Kommerell B Z Gastroenterol; 1984 Apr; 22(4):182-7. PubMed ID: 6328781 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathological features of hepatocellular carcinoma--comparison of hepatitis B seropositive and seronegative patients. Okuda H; Obata H; Motoike Y; Hisamitsu T Hepatogastroenterology; 1984 Apr; 31(2):64-8. PubMed ID: 6202615 [TBL] [Abstract][Full Text] [Related]
13. [Hepatita B and C virus infections in patients with hepatocellular carcinoma]. Crespo J; Dueñas C; Sánchez-Antolín G; Fábrega E; Carte B; Pons-Romero F Med Clin (Barc); 1996 Feb; 106(7):241-5. PubMed ID: 8667672 [TBL] [Abstract][Full Text] [Related]
14. [Hepatitis B virus DNA detection by means of polymerase chain reaction in patients with chronic hepatitis and hepatocellular carcinoma]. Song Y; Pan W; Fan Z; Du P; Qi Z Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):220-2. PubMed ID: 15617333 [TBL] [Abstract][Full Text] [Related]
15. [Clinical significance of HBeAg and anti-HBe in HBsAg positive liver diseases]. Takahashi A; Sekiya C; Yazaki Y; Tominaga Y; Oohara K; Ono M; Sato H; Hasebe C; Namiki M Hokkaido Igaku Zasshi; 1983 Jan; 58(1):30-42. PubMed ID: 6840666 [TBL] [Abstract][Full Text] [Related]
16. HBeAg/anti-HBe antigenic system in liver diseases in Greece. Theodoropoulos G; Nakopoulou L; Fertakis A; Papaevangelou G; Hadzis G; Kasfiki A Hepatogastroenterology; 1983 Dec; 30(6):243-5. PubMed ID: 6327477 [TBL] [Abstract][Full Text] [Related]
17. Incidences of HBeAg and anti-HBe in, and clinical course of hepatitis B virus carriers. Tsuchie H; Kurimura O; Tamura I; Shimase K; Kaneto E; Kurimura T; Tsuda F; Mayumi M Biken J; 1984 Dec; 27(4):169-76. PubMed ID: 6100353 [TBL] [Abstract][Full Text] [Related]
18. Presence of antibodies to the hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non-Asians in Los Angeles County, California. Yu MC; Yuan JM; Ross RK; Govindarajan S Hepatology; 1997 Jan; 25(1):226-8. PubMed ID: 8985295 [TBL] [Abstract][Full Text] [Related]
19. Analysis of risk factors for hepatocellular carcinoma in patients with HBs antigen- and anti-HCV antibody-negative alcoholic cirrhosis: clinical significance of prior hepatitis B virus infection. Uetake S; Yamauchi M; Itoh S; Kawashima O; Takeda K; Ohata M Alcohol Clin Exp Res; 2003 Aug; 27(8 Suppl):47S-51S. PubMed ID: 12960507 [TBL] [Abstract][Full Text] [Related]
20. Clinical features of hepatocellular carcinoma seronegative for both HBsAg and anti-HCV antibody but positive for anti-HBc antibody in Japan. Yano Y; Yamashita F; Sumie S; Ando E; Fukumori K; Kiyama M; Oyama T; Kuroki S; Kato O; Yamamoto H; Tanaka M; Sata M Am J Gastroenterol; 2002 Jan; 97(1):156-61. PubMed ID: 11808941 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]